















   


















ALCOHOL WITHDRAWAL AND 
RELAPSE PREVENTION 
  Alcohol use disorder1 (AUD) is a chronic, recurring disease that requires ongoing, personalized interdisciplinary 
management.
  Even if the individual does not have AUD, a sudden reduction in or cessation of prolonged, heavy drinking can lead to 
a withdrawal syndrome that, if left untreated, can cause serious complications.
  The management of AUD involves both treatment for withdrawal and treatment for preventing relapses, both of 
which should, when applicable, be offered at the same time to ensure the continuity of care.
1. In this guide, the term “alcohol” refers specifically to ethanol.
  The following items should be checked or checked for during the initial assessment of a patient with AUD in order to 
assess their alcohol misuse and risk of withdrawal syndrome and to guide the choice of treatment.
• Their pattern of alcohol and other psychoactive 
substances use:
 – The quantity and frequency
 – When last used
 – The use context and impact
•   Risk factors for withdrawal-related complications
• Their treatment history and goals, and their 
preferences regarding the different aspects of the 
treatment
• The presence of a history of other physical or mental 
health problems, including signs of depression or 
suicidal ideation
• Their social environment
  Alcohol misuse can be assessed by means of a validated instrument like the AUDIT Alcohol Use Disorders 
Identification Test) or the instrument DÉBA-Alcool (Assessment and Screening of Assistance Needs – Alcohol). 
However, the diagnosis of AUD is based on DSM-5 criteria.
  The misuse of other psychoactive substances can be assessed with the ASSIST scale (Alcohol, Smoking and Substance 
Involvement Screening Test).
LABORATORY TESTS
  The following tests should be ordered when assessing the patient’s condition or as soon as possible. However, treatment 
initiation should not be delayed if alcohol withdrawal is suspected and the laboratory test results are not yet available.
GENERAL INFORMATION
INITIAL ASSESSMENT
This optimal use guide is intended for health professionals. It is provided for information purposes only and should not replace the judgment of the clinician who performs activities reserved under a statute or 
regulation. The recommendations concern individuals 18 years of age and older, with the exception of pregnant or breastfeeding women. They were developed using a systematic process and are supported by 




 F Complete blood count  (CBC)
 F International normalized ratio 
(INR)
 F Electrolyte profile
 F Total bilirubin
 F Aspartate aminotransferase 
(AST)
 F Alanine aminotransferase 
(ALT)





AS NECESSARY, DEPENDING ON THE SITUATION
For women of child-bearing potential:
 F Chorionic gonadotropin hormone (β-hCG) 
In the presence of risk factors2:
 F Hepatitis B
 F Hepatitis C
 F Human immunodeficiency virus (HIV)
 F Syphilis
  A GGT (gamma-glutamyl transferase) assay may sometimes be considered in order to supplement the alcohol 
use assessment.
  Consider ordering a urine toxicology screen only if you strongly suspect the misuse of other substances.
2. For additional information on sexually transmitted and blood-borne infections (STBBI), consult the MSSS’s table ITSS à rechercher selon les facteurs de 






























   
   


















  Validated instruments are available and should be used when assessing the patient’s condition, including: 
• For assessing the risk of alcohol withdrawal-related complications: the PAWSS (Prediction of Alcohol Withdrawal  
Severity Scale);
• For assessing the severity of active alcohol withdrawal syndrome1
 – The CIWA-Ar (Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised) combined with the 
measurement of the patient’s vital signs, especially their heart rate; 
 – Or the Modified CIWA if the care context limits the use of the CIWA-Ar.
  Determine if the patient has Gayet-Wernicke encephalopathy using Caine’s criteria.
1.  The SAWS (Short Alcohol Withdrawal Scale) is also available. The questionnaire can be completed by the patient or an outside evaluator.
RISK FACTORS FOR WITHDRAWAL-RELATED COMPLICATIONS
The risk of withdrawal-related complications increases with the presence of several factors, each of which represents 
an additional risk. Therefore, in addition to the initial assessment of the patient’s condition, these factors should be 
checked for:
• The presence of moderate or severe active withdrawal 
syndrome on presentation;
• A history of severe withdrawal or withdrawal-related  
complications (e.g., hallucinations, seizures or delirium 
tremens);
• Previous multiple withdrawals, especially if close 
together;
• Age > 65 years;
• Pronounced autonomic nervous system hyperactivity 
(e.g., tachycardia, diaphoresis and hypertension);
• The presence of physical or medical comorbidities or 
traumatic brain injury;
• A physiological dependence on benzodiazepines,  
barbiturates or other  GABAergic agents;
• The concomitant use of other psychoactive substances.
TREATMENT PRINCIPLES
  Pharmacological treatment for withdrawal:
• Should be administered in the presence:
 – Of moderate to severe active withdrawal syndrome (CIWA-Ar score ≥ 8 or Modified CIWA score ≥ 7); OR
 – Of a high risk of withdrawal-related complications (PAWSS score ≥ 4).
• Should be considered in the presence:
 – Of a low risk of withdrawal-related complications (PAWSS score < 4); AND
 – Of mild active withdrawal syndrome (CIWA-Ar score < 8 or Modified CIWA score < 7); OR
 – Of a risk of developing withdrawal syndrome upon stopping or reducing alcohol use.
 – For these individuals, consideration should be given to outpatient management.
  In an outpatient setting
• Consideration should be given to dose-splitting and a high pharmacy dispensing frequency, both for 
benzodiazepines and gabapentin, in order to monitor their use (to limit the potential for abuse and the risk of 
overdose or diversion) and to ensure a better patient follow-up;
• To ensure a satisfactory follow-up, initiate treatment according to the treatment staff’s availability and see to it 
that a support person is available throughout the withdrawal period.
  In a hospital setting
• In the case of benzodiazepines, when possible, preference should be given to a symptom-triggered dosage regimen;
• However, consideration may be given to administering benzodiazepines using a decreasing fixed-dose schedule, 
especially in the following situations:
 – When close monitoring tailored to the patient’s condition is not possible,
 – For patients currently taking benzodiazepines daily,
 – If the patient has an unstable psychiatric comorbidity or a coexisting addiction,































   
   


























Duration of action Intermediate Long Intermediate
Active metabolites No Yes No
Mild to moderate withdrawal 
syndrome with a low risk of 
complications (CIWA-Ar score < 
19 or Modified CIWA score < 12 
and PAWSS score < 4)
OU
Low risk of developing 
withdrawal syndrome
100-300 mg PO TID (+/- PRN).
Increase gradually to a maximum 
of 1800 mg daily as tolerated
Renal impairment:
CrCl 30 to 59 ml/min:
Limit to 300 mg PO BID
CrCl 15 to 29 ml/min:
Limit to 300 mg PO QD
CrCl < 15 ml/min:
Initiate and limit to 100 mg PO QD
Adjust the dose for patients over 
65 years of age3
5-10 mg PO q 4 to 6 h PRN
OR
5-10 mg PO TID or QID (+/- HS PRN)
Adjust the dose and, when 
possible, avoid in patients over 
65 years of age, especially in an 
outpatient setting.3
1-2 mg PO/SL q 4 to 6 h PRN
OR
1-2 mg PO/SL TID or QID (+/- HS PRN)
Adjust the dose for patients over 
65 years of age3
Severe withdrawal syndrome4
(CIWA-Ar score ≥ 19 or Modified 
CIWA score ≥ 12)
10-20 mg q 1 to 2 h PRN (preferably 
via the parenteral route5)
2-4 mg q 1 to 2 h PRN (preferably 
via the parenteral route)
High risk of severe withdrawal 
syndrome or of complications4
 
Initiate treatment very promptly to prevent severe withdrawal syndrome
Limit dose requiring a 
reassessment Not applicable > 60 mg in 12 hours > 12 mg in 12 hours
Dose reduction when the patient’s 
condition is stabilized (e.g., CIWA-
Ar score < 8 or Modified CIWA 
score < 7 for 12-24 hours)
Stepwise by 100-200 mg PO TID   
for 3 to 7 days, unless continued  
for relapse prevention
Decrease over 3 to 7 days by reducing the dose or frequency
Duration of treatment
  7 to 10 days
  However, consideration may be given to extending the duration of treatment up to a maximum of 4 weeks in 
the event of persistent withdrawal symptoms, a brief, isolated relapse, or benzodiazepine dependence
PRECAUTIONS AND CONTRAINDICATIONS




Severe or chronic respiratory 
impairment
Renal impairment (CrCl in ml/min) (< 60) 6 6




Drug interactions For a list (nonexhaustive), see the table showing the main drug interactions in Appendix I.
Legend:             :Recommended;             :May be considered with caution, depending on the risks and benefits;            :Not recommended.
1. These drugs are not approved by Health Canada for the treatment of alcohol withdrawal, but they are commonly prescribed for this purpose and are valid treatment options, based on the clinical 
expertise of the advisory committee’s members.
2. Gabapentin is an even more favorable option for the treatment of withdrawal when its use is also being considered for relapse prevention.
3. In patients over 65 years of age, start with lower doses to reduce the risk of falls or respiratory depression.
4. Phenobarbital is not approved by Health Canada for the treatment of alcohol withdrawal. However, it is sometimes prescribed for this purpose and is a valid treatment option for severe, complicated 
withdrawal syndrome, based on the clinical expertise of the advisory committee’s members. However, its use should be reserved for an experienced prescriber practicing in a hospital setting.
5. For the administration of high diazepam doses, the intrarectal route may be preferable to the IM route when the IV route is not available.






























   
   


















  Thiamine1 100 to 500 mg/day PO, IV or IM for 1 week. Adjust the dose according to the patient’s condition (e.g., 
the severity of the withdrawal syndrome, their ability to take food, impaired absorption, diarrhea or Wernicke 
encephalopathy).
  If the patient has confirmed deficiencies, correct the electrolyte abnormalities, especially with regard to magnesium 
(which is necessary for the absorption of thiamine into cells).
1. Since thiamine is poorly absorbed via the oral route, the parenteral route is to be preferred (in a hospital setting, preference should first be given to the IV route and then to the IM route). If the oral 
route is used, the daily dose can be split to promote better absorption. 
FOLLOW-UP
  The medication doses and the frequency at which the patient is assessed should be adjusted during treatment 
according to changes in their withdrawal symptoms (e.g., based on a validated instrument) and according to their 
health status, history of complications, social support, and environment.
  In an outpatient setting, explain to them the details regarding their treatment (see follow-up sheet):
• A follow-up should be provided 2 or 3 times a week (minimally within 24 to 72 hours after the start of treatment) 
by a member of the treatment team, including, among others, the pharmacist, and include checking or checking 
for the following:
 – The use of alcohol or other psychoactive substances;
 – Evidence of underdosing (marked withdrawal symptoms), overdosing or intoxication with the medication or 
other substances;
 – Therapeutic compliance;
 – Changes in their emotional status (e.g., suicidal ideation).
• Additional monitoring should be considered for patients with a benzodiazepine use disorder (current or past). 
  In an institutional setting, a close follow-up should be provided at least after the first 2 or 3 doses of the treatment 
until the withdrawal signs and symptoms are controlled.
•  The level of sedation should be assessed (e.g., the Richmond Agitation Sedation Scale  (RASS)).
  A prescription to prevent relapses should be considered pending management for the treatment follow-up. 
REFERRAL TO A HOSPITAL or CONSULTATION WITH AN EXPERIENCED COLLEAGUE
  Consideration should be given to referring the patient to a hospital in the following situations:
• Severe withdrawal syndrome (e.g., hallucinations, CIWA-Ar score ≥ 19 or Modified CIWA score ≥ 13) or a high risk 
of withdrawal-related complications (PAWSS > 4);
• Suspected Gayet-Wernicke encephalopathy;
• Worsening of overall health (e.g., pronounced sedation or unstable vital signs).
  Consideration should be given to consulting an experienced colleague in the following situations:
• A history of severe withdrawal syndrome or of withdrawal-related complications;
• A lack of response after 24 to 48 hours of treatment (CIWA-Ar score ≥ 8 or Modified CIWA score ≥ 7);
• Multiple, severe or unstable physical or psychiatric comorbidities (including suicidal ideation);
• A concurrent disorder involving the use of another substance, with the exception of tobacco.
  A lower hospital admission threshold may be considered in certain situations, such as for individuals over age 65 or 






























   
   

















  TREATMENT PRINCIPLES
  Pharmacotherapy for relapse prevention should be offered to individuals with AUD.
  The following elements in particular should be taken into consideration when choosing a pharmacological treatment:
• The treatment goals (e.g., a reduction in alcohol use1 or abstinence, or the treatment of anxiety or sleep 
disturbances). These goals can change along the way;
• The patient’s past treatment experiences (including tolerance and the maximum dose reached), needs and 
preferences.
  Diversity should be taken into consideration in the patient’s management, both for certain physiological and 
sociocultural aspects (e.g., the perception of treatments).
  Medication for relapse prevention can be safely introduced when the patient is using alcohol, but its effectiveness may 
be greater when it is administered at the end of a withdrawal management period.
• However, it is preferable to have eliminated most of the effects of withdrawal before initiating treatment so 
that there is no confusion between the clinical picture and the medications’ adverse effects, and to adjust the 
management according to the residual withdrawal symptoms.
  Pharmacotherapy should be accompanied by:
• Brief interventions and counselling to equip the patient to deal with the difficulties associated with drinking;
• Motivational support for achieving their goals and encouraging therapeutic adherence;
• A proposal for psychosocial interventions and support2, although these interventions are not to be perceived as 
conditional or mandatory for accessing treatment for AUD.
  Consideration should be given to prescription-splitting and a high pharmacy dispensing frequency, especially at the start 
of treatment and especially for gabapentin and topiramate, in order to monitor their use and to ensure a better patient 
follow-up.
  It is important to remind women who are pregnant or of childbearing potential that the use of topiramate during 
pregnancy carries significant risks for the fetus (support contraception needs, if applicable).
1. Any objective aimed at reducing average alcohol use is likely to be beneficial and should be fostered.
2.  If need be, consult the MSSS’s Répertoire des ressources en dépendances.
RELAPSE PREVENTION
PHARMACOLOGICAL TREATMENTS3
1st  choice 2nd choice
Dosage
Naltrexone Acamprosate4 Gabapentin5 Topiramate5
25 mg PO QD
for 2 to 4 days, then 50 mg 
PO QD
666 mg PO TID
< 60 kg: 
666 mg AM, 333 mg PM and 
333 mg HS
100-300 mg PO TID. 
Increase gradually to 
1200-18006 mg PO  daily as 
tolerated
25 mg PO QD. Increase 
gradually (e.g., increase 
stepwise by 25 mg a week) 
to 100-150 mg PO BID as 
tolerated
CrCl 30 to 49 ml/min: 
333 mg PO TID
CrCl 30 to 59 ml/min:
Limit to 300 mg PO BID
Clcr 15 to 29 ml/min :
Limit to 300 mg PO QD
Clcr < 15 ml/min:
Initiate and limit to 100 mg  
PO QD
Clcr < 70 ml/min : 
target dose 50 to 75 mg  
PO BID
3. The current evidence does not support recommending the use of baclofen for relapse prevention.
4. Acamprosate, an attractive option when the patient’s treatment goal is abstinence, is an exception drug in the RAMQ’s formulary. The indication for payment is recognized for maintenance of 
abstinence in patients with alcohol dependence who have abstained from alcohol for at least 5 days and who are part of a comprehensive management program focused on alcohol abstinence. The 
maximum duration of each authorization is 3 months, for a total maximum duration of authorization of 12 months.
5. Gabapentin and topiramate are not approved by Health Canada for relapse prevention. However, they are commonly prescribed for this purpose and are valid treatment options, based on the clinical 
expertise of the advisory committee’s members.
6. Gabapentin may be effective at 900 mg/day in some patients, but its efficacy appears to be greater at a dose of 1200 mg/day. Following alcohol withdrawal with gabapentin, adjust as needed to the 
































   
   


















Naltrexone Acamprosate Gabapentin Topiramate
Hepatic impairment (Child-Pugh C)
Opioids: current 
or anticipated use, 




(CrCl in ml/min (< 60) (≤ 30) (30-49) (< 60) (< 70)             
Age > 65 years
Drug interactions For a list (nonexhaustive), see the table showing the main drug interactions in Appendix I.
Duration of treatment
  Treatment for relapse prevention should be continued for at least 3 months.
  If there is no discernible benefit after 3 months of treatment, the treatment should be reevaluated and alternatives considered.
  Six months after the start of treatment, the usefulness of continuing the medication should be reevaluated with the patient on 
the basis of the perceived or experienced benefits and adverse effects.
  The administration of gabapentin or topiramate should not be stopped abruptly.
Legend:             :Recommended;             :May be considered with caution, depending on the risks and benefits;            :Not recommended.
1. Including opioid use during the past ten days, even if the patient is not actively using any.
FOLLOW-UP
  Patients should be monitored closely at the start of treatment (e.g., once a week). This should include checking or 
checking for the following:
• The onset or worsening of sleep disturbances, symptoms of depression or anxiety, or suicidal ideation, even 
without alcohol use;
• The onset of withdrawal symptoms, especially for patients without prior withdrawal management;
• Tolerance of and compliance with the treatment, and cravings for alcohol. 
  Next, a follow-up should be conducted at least once a month for 6 months by a member of the multidisciplinary              
team (except the psychosocial workers) and with reduced but regular frequency if the treatment is continued beyond         
6 months.
  It may be beneficial to take steps to promote therapeutic compliance: 
• In the event of therapeutic noncompliance (rather than discontinuing the medication);
• In the event of instability or social precariousness (e.g., homelessness).
  Additional follow-ups, depending on the medication:
• Topiramate: Monitor the patient for the onset of metabolic acidosis;
• Naltrexone: A liver profile should be run 4 to 6 weeks after the start of treatment and every 6 months thereafter.
  Consideration could be given to referring the patient to a specialized facility or to intensifying the outpatient follow-up, 
as the case may be, in the following situations:
• The onset or worsening of a severe, unstable or complex physical or mental health problem (e.g., bipolar disorder 
or psychotic disorder, such as schizophrenia);
• The onset or worsening of another substance use disorder, with the exception of tobacco and cannabis;
• A deterioration in the social environment or psychosocial destabilization;
• No benefit obtained despite several adequate treatment attempts.
  Following treatment, the absence of AUD criteria for a period of more than 3 months but less than 12 months is 
considered early remission, whereas a symptom-free period of more than 12 months is considered sustained remission




Most significant drug interactions





• Central nervous system depressants 
(e.g., opioids, alcohol, anesthetics, 
antidepressants, sedative 
antihistamines, antipsychotics and 
hypnotics)
Increased risk                                                    
of respiratory depression
Diazepam
• CYP2C19 or CYP3A4  inhibitors, such as: 
 – Azole antifungals (itraconazole, 
ketoconazole and voriconazole)
 – Fluvoxamine
 –  HIV protease inhibitors









Altered serum phenytoin                           
and digoxin levels.
Gabapentine
CNS depressants, including opioids, 
benzodiazepines and alcohol
Increased effects on cognitive functions 
and gross motor skills and increased risk 
of sedation and respiratory depression. 
Aluminum hydroxide- and magnesium-
based antacids
Decreased gabapentin  levels                   
(take 2 hours apart).
Naltrexone
Other potentially hepatotoxic drugs Increased risk of hepatotoxicity.
Opioids
Decrease in the effect of opioids 
and possible precipitation of opioid 
withdrawal syndrome.
Topiramate
Oral contraceptives Decreased concentrations and effectiveness of oral contraceptives.
There are several other significant drug 
interactions with topiramate
If necessary, consult a member of the 
interprofessional team.
ALCOHOL USE DISORDERS IDENTIFICATION TEST (AUDIT)
The Alcohol Use Disorders Identification Test (AUDIT) : interview version. 
Read questions as written. Record answers carefully. Begin the AUDIT by saying “Now I am going to ask you some questions about 
your use of alcoholic beverages during this past year.”
Explain what is meant by “alcoholic beverages” by using local examples of beer, wine, vodka, etc. Code answers in terms of “standard 
drinks”. Place the correct answer number in the box at the right. 
1. How often do you have a drink containing alcohol?
(0) Never
(1) Monthly or less
(2) 2 to 4 times a month
(3) 2 to 3 times a week
(4) 4 or more times a week
6. How often during the last year have you needed a first drink in the morning to 
get yourself going after a heavy drinking session?
(0) Never
(1) Less than monthly
(2) Monthly
(3) Weekly
(4) Daily or almost daily
2. How many drinks containing alcohol do you have on a typical day 
when you are drinking?
(0) one or two
(1) three or four
(2) five or six
(3) seven to nine 
(4) ten or more
7. How often during the last year have you had a feeling of guilt or remorse 
after drinking?
(0) Never
(1) Less than monthly
(2) Monthly
(3) Weekly
(4) Daily or almost daily
3. How often do you have six or more drinks on one occasion?
(0) Never
(1) Less than monthly
(2) Monthly
(3) Weekly
(4) Daily or almost daily
8. How often during the last year have you been unable to remember what 
happened the night before because you had been drinking?
(0) Never
(1) Less than monthly
(2) Monthly
(3) Weekly
(4) Daily or almost daily
4. How often during the last year have you found that you were not able 
to stop drinking once you had started?
(0) Never
(1) Less than monthly 
(2) Monthly
(3) Weekly
(4) Daily or almost daily
9. Have you or someone else been injured as a result of your drinking?
(0)     No
(2)     Yes, but not in the last year
(4)     Yes, during the last year
5. How often during the last year have you failed to do what was 
normally expected from you because of drinking?
(0) Never
(1) Less than monthly 
(2) Monthly
(3) Weekly
(4) Daily or almost daily
10. Has a relative or friend or a doctor or another health worker been concerned 
about your drinking or suggested you cut down?
(0)     No
(2)    Yes, but not in the last year
(4)    Yes, during the last year
Score total : ________________ (maximum score = 40)
Source: https://www.who.int/publications/i/item/audit-the-alcohol-use-disorders-identification-test-guidelines-for-use-in-primary-health-care
APPENDIX 2
Return to optimal use guide
PREDICTION OF ALCOHOL WITHDRAWAL SEVERITY SCALE (PAWSS)
APPENDIX 3
Part A: Threshold criteria Yes or no                     (no points)
Have you consumed any amount of alcohol (i.e., been drinking) within the last 30 days?
Did the patient have a positive blood alcohol level on admission?
If the answer to either question is Yes, proceed with test.
Part B: Based on patient interview (1 point each)
Have you been recently intoxicated/drunk, within the last 30 days?
Have you ever undergone alcohol use disorder rehabilitation treatment or treatment for alcoholism?                  
(i.e., in-patient or out-patient treatment programs or AA attendance) 
Have you ever experienced any previous episodes of alcohol withdrawal, regardless of severity?
Have you ever experienced blackouts?
Have you ever experienced alcohol withdrawal seizures?
Have you ever experienced delirium tremens or DT’s?
Have you combined alcohol with other “downers” like benzodiazepines or barbiturates, during the last 90 days?
Have you combined alcohol with other substance of abuse, during the last 90 days?
Part C: Based on clinical evidence (1 point each)
Was the patient’s blood alcohol level on presentation greater than  43 mmol/l? OR Have you consumed any 
alcohol in the past 24 jours?
Is there any evidence of increased autonomic activity? (e.g., heart rate > 120 bpm, tremor, sweating, agitation 
or nausea)
Total score
Notes: Maximum score =10. This instrument is intended as a screening tool. The greater the number of positive findings, the higher 
the risk for the development of alcohol withdrawal syndrome.
A score ≥ 4 suggests high risk for moderate to severe (complicated) alcohol withdrawal syndrome.
Source: Maldonado JR, Sher Y, Das S, Hills-Evans K, Frenklach A, Lolak S, et al. Prospective validation study of the Prediction of Alcohol Withdrawal 
Severity Scale (PAWSS) in medically ill inpatients: A new scale for the prediction of complicated alcohol withdrawal syndrome. Alcohol Alcohol 
2015;50(5):509-18.
Return to optimal use guide
CLINICAL INSITITUTE WITHDRAWAL ASSESSMENT ALCOHOL REVISED SCALE (CIWA-Ar)
Heart rate: _________/ min                             Blood pressure: _________ / _________
Nausea and vomiting: Ask ”Do you feel sick to your stomach? Have you 
vomited?”  Observe.




4     Intermittent nausea with dry heaves
5
6
7    Constant nausea, frequent dry heaves and vomiting
Tactile disturbances: Ask «Have you any itching, any pins and needles, any 
burning or any numbness, or do you feel bugs crawling on or under your skin?»
0     No disturbances of this type
1     Very mild itching, pins and needles, burning or numbness
2     A mild degree of the above-mentioned disturbances
3     A moderate degree of the above-mentioned disturbances 
4     Moderately severe hallucinations
5     Severe hallucinations
6     Extremely severe hallucinations
7     Continuous hallucinations
Tremors: Evaluate with arms extended and fingers in front of the 
examiner. Observe.
0     No tremors
1     Not visible, but can be felt at the fingertips
2
3
4     Moderate, with the patient’s arms extended
5
6
7     Severe, even with arms not extended
Auditory disturbances: Ask «Are you more aware of the sounds around you? 
Are they harsher? Do they frighten you? Are you hearing any sound that is 
disturbing to you? Are you hearing things you know are not there?»
0     No disturbing sounds
1     Very mild harshness or ability to frighten
2     Mild harshness or ability to frighten
3     Moderate harshness or ability to frighten
4     Moderately severe hallucinations
5     Severe hallucinations
6     Extremely severe hallucinations
7     Continuous hallucinations
Paroxysmal sweats: Observe.
0      No sweat visible
1      Sweat barely perceptible, palms moist
2
3
4     Beads of sweat on forehead
5
6
7     Drenching sweats
Visual disturbances: Ask «Does the light appear to be too bright? Is its color 
different? Does it hurt your eyes? Are you seeing anything that is disturbing to 
you? Are you seeing things you know are not there?»
0     No disturbances of this type
1     Very mild sensitivity
2     Mild sensitivity
3     Moderate sensitivity
4     Moderately severe hallucinations
5     Severe hallucinations
6     Extremely severe hallucinations
7     Continuous hallucinations
Anxiety: Ask “Do you feel nervous?” Observe.
0     No anxiety, at ease.
1     Mildly anxious
2
3
4     Moderately anxious, or guarded, so anxiety is inferred
5
6
7     Equivalent to acute panic states as seen in severe delirium or 
acute schizophrenic reactions
Headaches: Ask «Does your head feel different? Does it feel like there is a band 
around your head?» Do not rate for dizziness or light-headedness. Focus instead 
on severity.
0     No headache
1     Very mild 
2     Mild 
3     Moderate 
4     Moderately severe 
5     Severe 
6     Very severe 
7     Extremely severe
Agitation: Observe.
0     Normal activity
1     Somewhat more than normal activity
2
3
4    Moderately fidgety and restless
5
6
7     Paces back and forth during the evaluation or thrashes about  
Orientation disturbances: Ask “What day is this? Where are you? Who am I?”
0     Oriented and can do serial additions
1     Cannot do serial additions or is uncertain about date
2     Gets date wrong by no more than 2 days
3     Gets date wrong by more than 2 days
4     Disoriented for place and/or person 
Score total : ________________ (Score maximum = 67)
APPENDIX 4
When interpreting the score, one must take into account the data from the clinical evaluation and any confounding fac-
tors (e.g., the effect of medications, medical conditions, communication difficulties).
Severity of alcohol withdrawal syndrome as assessed by the CIWA-Ar
Severity Mild Moderate Severe
Score < 8 8 to 18 ≥ 19
Return to optimal use guide
APPENDIX 5









150/90 to 180/95 2
> 180/95 3
Nausea or vomiting
No nausea or vomiting 0
Mild nausea with dry heaves 1
Constant nausea with vomiting 2
Tremors
No tremors 0
Palpable at fingertips only 1
Moderate and grossly visible 2
Severe, even with arms at side 3
Anxiety
No anxiety or agitation 0
Mildly anxious with increased activity 1
Moderately anxious with restlessness 2
Severely anxious with near-panic reaction 3
Disorientation/confusion
Oriented 0
Mild — uncertain about date or place 1
Moderate — disoriented as to time, place and person and surrounding events 2
Severe — completely disoriented as to time, place and person or has auditory, tactile or visual disturbances 3
Perspiration
None 0
Mild – barely perceptible with moist palms 1
Severe — drenching sweats 2
Total score
(Maximum score =18)
Modified version of the Clinical Institute Withdrawal Assessment for Alcohol Scale (Modified CIWA-Ar)
Source : WOJTECKI CA, MARRON J, ALLISON EJ JR, KAUL P, TYNDALL G. Systematic ED assessment and treatment of alcohol withdrawal syndromes: a 
pilot project at a Veterans Affairs Medical Center. J Emerg Nurs. 2004 Apr; 30(2):134-40.
Severity of alcohol withdrawal syndrome as assessed by the Modified CIWA-Ar
Severity Mild Moderate Severe
Score 0 to 6 7 to 12 ≥ 13
Return to optimal use guide
APPENDIX 6
RICHMOND AGITATION-SEDATION SCALE (RASS)
Instruction Description/Definition Level
Observe the patient quietly
If he/she shows spontaneous motor 
activity, assess the level of agitation:
Combative: immediate danger to staff + 4
Very agitated: pulls or removes tubes or catheters and/or is 
aggressive toward staff + 3
Agitated: frequent non-purposeful movements and/or fights 
ventilator + 2
Restless: anxious or apprehensive, but movements oriented, 
infrequent and not vigorous or aggressive + 1
If he/she is calm and responds or not to 
simple commands:
Alert and calm: eyes open spontaneously
Conscious: RASS 0 + responds to simple commands 0
If he/she is calm and eyes are open: assess 
the level of hypoalertness (or drowsiness), 
state the patient’s name, but without 
touching him/her, in an increasingly 
louder voice and in an especially loud 
voice if he/she might be hearing-
impaired (elderly patient, prolonged 
stay in resuscitation: a plug of earwax, 
antibiotic or furosemide toxicity): 
Drowsy: not fully alert but has sustained awakening, with eye 
contact to voice (> 10 s) – 1
Slight sedation: briefly awakens, with eye contact to voice (< 10 s) – 2
Moderate sedation: movement or eye opening to voice , but no eye 
contact – 3
If the patient makes no movement, 
including when his/her name is called 
loudly: rub the shoulder and then the 
sternum in a non-nociceptive manner: 
Deep sedation: no movement in response to voice, but movement 
or eye opening to physical stimulation (non-nociceptive rubbing of 
the shoulder or sternum)  
– 4
Unarousable: no response to voice or physical stimulation (non-
nociceptive rubbing of shoulder and sternum) – 5
Source: CMQ, 2015. La sédation-analgésie, lignes directrices.
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